Nanobiotix (NBTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanobiotix (NBTX) has a cash flow conversion efficiency ratio of 0.190x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.01 Million) by net assets ($-84.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NBTX net asset quality index to measure how much of total assets are equity-financed.
Nanobiotix - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Nanobiotix's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NBTX cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Nanobiotix Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanobiotix ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Primaris Retail R.E. Invest. Tr. Units
TO:PMZ-UN
|
0.008x |
|
NOS S.G.P.S. S.A.
LS:NOS
|
0.145x |
|
Zhejiang Transfar Co Ltd
SHE:002010
|
0.006x |
|
BlackRock Science and Technology Trust II
NYSE:BSTZ
|
-0.019x |
|
Foryou Corp
SHE:002906
|
0.041x |
|
Henan Dayou Energy Co Ltd
SHG:600403
|
0.002x |
|
Okeanis Eco Tankers Corp
OL:OET
|
0.087x |
|
NCR Atleos Corporation
NYSE:NATL
|
0.442x |
Annual Cash Flow Conversion Efficiency for Nanobiotix (2011–2025)
The table below shows the annual cash flow conversion efficiency of Nanobiotix from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Nanobiotix market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-84.48 Million | $-33.42 Million | 0.396x | +32.95% |
| 2024-12-31 | $-65.70 Million | $-19.55 Million | 0.298x | -95.60% |
| 2023-12-31 | $-1.84 Million | $-12.48 Million | 6.766x | +393.17% |
| 2022-12-31 | $-27.05 Million | $-37.10 Million | 1.372x | +223.04% |
| 2021-12-31 | $26.79 Million | $-29.87 Million | -1.115x | -185.33% |
| 2020-12-31 | $70.47 Million | $-27.54 Million | -0.391x | -101.81% |
| 2019-12-31 | $-1.91 Million | $-41.17 Million | 21.566x | +1282.07% |
| 2018-12-31 | $14.24 Million | $-25.98 Million | -1.824x | -282.51% |
| 2017-12-31 | $43.92 Million | $-20.95 Million | -0.477x | +54.61% |
| 2016-12-31 | $17.40 Million | $-18.28 Million | -1.051x | +2.47% |
| 2015-12-31 | $15.61 Million | $-16.82 Million | -1.077x | -281.37% |
| 2014-12-31 | $30.32 Million | $-8.56 Million | -0.283x | +86.84% |
| 2013-12-31 | $3.18 Million | $-6.83 Million | -2.147x | -511.35% |
| 2012-12-31 | $10.70 Million | $-3.76 Million | -0.351x | +93.33% |
| 2011-12-31 | $925.53K | $-4.87 Million | -5.265x | -- |
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small … Read more